Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | HTT | P42858 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.67 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8769978 | 0.90 | MAPT (0.70) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4250152 | 0.89 | MAPT (0.73) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4251030 | 0.88 | MAPT (0.86) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4737529 | 0.88 | KCNQ3 (0.73) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4247530 | 0.86 | MAPT (0.69) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL3461764 | 0.85 | MAPT (0.64) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4497793 | 0.82 | DGAT1 (0.82) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4250462 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL4247068 | 0.81 | MAPT (0.62) | MAPTSMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL12978194 | 0.81 | SMN1; SMN2 (0.65) | MAPTSMN1; SMN2LMNAHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MAPT 759/4885SMN1; SMN2 155/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.